PT2825156T - Aminoácidos lipídicos de direcionamento - Google Patents
Aminoácidos lipídicos de direcionamentoInfo
- Publication number
- PT2825156T PT2825156T PT137102935T PT13710293T PT2825156T PT 2825156 T PT2825156 T PT 2825156T PT 137102935 T PT137102935 T PT 137102935T PT 13710293 T PT13710293 T PT 13710293T PT 2825156 T PT2825156 T PT 2825156T
- Authority
- PT
- Portugal
- Prior art keywords
- lipids
- targeting
- targeting aminoacid
- aminoacid lipids
- aminoacid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12001803 | 2012-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2825156T true PT2825156T (pt) | 2017-11-02 |
Family
ID=47901004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT137102935T PT2825156T (pt) | 2012-03-16 | 2013-03-11 | Aminoácidos lipídicos de direcionamento |
Country Status (21)
Country | Link |
---|---|
US (2) | US9878044B2 (pt) |
EP (1) | EP2825156B1 (pt) |
JP (2) | JP6527331B2 (pt) |
KR (2) | KR102208586B1 (pt) |
CN (1) | CN104168888A (pt) |
AU (2) | AU2013231638B2 (pt) |
BR (1) | BR112014022451B1 (pt) |
CA (1) | CA2867169C (pt) |
DK (1) | DK2825156T3 (pt) |
ES (1) | ES2644778T3 (pt) |
HK (1) | HK1198924A1 (pt) |
IL (1) | IL234550A (pt) |
MX (1) | MX354811B (pt) |
NO (1) | NO2825156T3 (pt) |
NZ (1) | NZ631034A (pt) |
PT (1) | PT2825156T (pt) |
RU (1) | RU2654210C2 (pt) |
SG (2) | SG11201405552VA (pt) |
TW (1) | TWI586370B (pt) |
WO (1) | WO2013135359A1 (pt) |
ZA (1) | ZA201407490B (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2347775T1 (sl) | 2005-12-13 | 2020-10-30 | President And Fellows Of Harvard College | Ogrodja za celično transplantacijo |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
PT2624873T (pt) | 2010-10-06 | 2020-03-04 | Harvard College | Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
RS63244B1 (sr) | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
EP2833892A4 (en) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY |
WO2013158673A1 (en) | 2012-04-16 | 2013-10-24 | President And Fellows Of Harvard College | Mesoporous silica compositions for modulating immune responses |
ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
AU2014329452B2 (en) | 2013-10-03 | 2019-06-20 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
SG11201608798YA (en) | 2014-04-23 | 2016-11-29 | Modernatx Inc | Nucleic acid vaccines |
WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
JP7094533B2 (ja) | 2015-04-10 | 2022-07-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫細胞捕捉デバイスおよびその製造および使用方法 |
WO2017041027A1 (en) * | 2015-09-04 | 2017-03-09 | Obi Pharma, Inc. | Glycan arrays and method of use |
AU2016324310B2 (en) | 2015-09-17 | 2021-04-08 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
CN105505382B (zh) * | 2015-12-04 | 2017-06-27 | 安徽师范大学 | 一种铜纳米簇溶液的制备方法及应用 |
WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
US11752238B2 (en) | 2016-02-06 | 2023-09-12 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
CN109311995A (zh) | 2016-03-29 | 2019-02-05 | 台湾浩鼎生技股份有限公司 | 抗体、药物组合物和方法 |
KR20180128496A (ko) | 2016-04-22 | 2018-12-03 | 오비아이 파머 인코퍼레이티드 | 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법 |
BR112018073683A2 (pt) | 2016-05-18 | 2019-02-26 | Modernatx, Inc. | polinucleotídeos codificadores de relaxina |
US11555177B2 (en) * | 2016-07-13 | 2023-01-17 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
CN110072545A (zh) | 2016-07-27 | 2019-07-30 | 台湾浩鼎生技股份有限公司 | 免疫原性/治疗性聚糖组合物及其用途 |
JP7121724B2 (ja) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ,インコーポレイテッド | ヒト抗体、医薬組成物及び方法 |
EP3500671A4 (en) * | 2016-08-17 | 2020-07-29 | The Broad Institute, Inc. | NEW CRISPR ENZYMS AND SYSTEMS |
EP3500670A4 (en) * | 2016-08-17 | 2020-08-19 | The Broad Institute, Inc. | NEW CRISPR SYSTEMS AND ENZYMES |
WO2018038549A1 (ko) * | 2016-08-24 | 2018-03-01 | 울산대학교 산학협력단 | Dtbp를 이용한 미생물 농축 또는 핵산 추출 방법 |
JP6793248B2 (ja) | 2016-08-24 | 2020-12-02 | インフュージョン テック | Dtbpを利用した微生物濃縮または核酸抽出方法 |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
CA3044274A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
DE17829597T1 (de) * | 2016-11-30 | 2019-12-05 | Noxxon Pharma Ag | Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz |
DK3596042T3 (da) | 2017-03-15 | 2022-04-11 | Modernatx Inc | Krystalformer af aminolipider |
AU2018234692B2 (en) | 2017-03-15 | 2022-06-02 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
US20200353062A1 (en) * | 2017-11-09 | 2020-11-12 | Immunovaccine Technologies Inc. | Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof |
TW202035444A (zh) | 2018-06-27 | 2020-10-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
US20220184223A1 (en) | 2019-03-13 | 2022-06-16 | Merck Patent Gmbh | Process for the preparation of lipidated proteinaceous structures |
MX2022003269A (es) | 2019-09-19 | 2022-07-04 | Modernatx Inc | Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos. |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2967069D1 (en) | 1978-01-16 | 1984-08-02 | Univ Boston | Effecting cellular uptake of molecules |
US4144034A (en) * | 1978-03-27 | 1979-03-13 | Texaco Inc. | Polyether-maleic anhydride reaction product containing motor fuel composition |
EP0142010B1 (de) | 1983-11-10 | 1987-12-23 | Hoesch Aktiengesellschaft | Verfahren und Vorrichtung zum elektrolytischen Abscheiden von Metallen |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6030954A (en) | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
IT1254135B (it) | 1992-01-16 | 1995-09-08 | Sigma Tau Ind Farmaceuti | Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica. |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
CN1263473A (zh) | 1997-05-21 | 2000-08-16 | 利兰·斯坦福青年大学托管委员会 | 增加跨生物膜转运的组合物和方法 |
JP5117648B2 (ja) * | 1999-04-20 | 2013-01-16 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | カチオン性peg脂質および使用方法。 |
AU7404800A (en) | 1999-09-30 | 2001-04-30 | Novo Nordisk A/S | A method for preparing conjugates between an antigen and mucosal binding component |
JP4678967B2 (ja) * | 2001-03-08 | 2011-04-27 | 本田技研工業株式会社 | ゲル化性有機化合物及びそれを用いるゲル |
GB0106041D0 (en) * | 2001-03-12 | 2001-05-02 | Cancer Res Ventures Ltd | Lipids and liposomes |
EP1572067A4 (en) | 2001-05-18 | 2009-05-13 | Sirna Therapeutics Inc | CONJUGATES AND COMPOSITIONS FOR CELL DELIVERY |
JP5093547B2 (ja) * | 2001-08-24 | 2012-12-12 | 日本ケミカルリサーチ株式会社 | 両イオン性脂質およびその用途 |
US20030138490A1 (en) | 2001-09-08 | 2003-07-24 | Zhibing Hu | Synthesis and uses of polymer gel nanoparticle networks |
EP1308167A1 (de) | 2001-11-06 | 2003-05-07 | Pickl, Winfried, Ao. Univ. Prof. Dr. | Antigenpräsentierende Vesikel |
JP4331927B2 (ja) * | 2002-08-29 | 2009-09-16 | 協立化学産業株式会社 | 無機ナノ粒子−有機化合物複合体およびそれの一次元配列集積構造体 |
AU2004248138B2 (en) * | 2003-05-29 | 2009-09-03 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
WO2006032705A2 (en) | 2004-09-23 | 2006-03-30 | Guerbet | Contrast agents encapsulating systems for cest imaging |
US20100028450A1 (en) | 2006-01-25 | 2010-02-04 | The Board Of Trustees Of The University Of Illinoi S | Tolerogenic biodegradable artificial antigen presenting system |
US20100104629A1 (en) | 2008-04-16 | 2010-04-29 | Abbott Laboratories | Cationic lipids and uses thereof |
US20090285881A1 (en) * | 2008-04-16 | 2009-11-19 | Abbott Laboratories | Cationic lipids and uses thereof |
WO2009129387A2 (en) * | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
RU2409587C2 (ru) * | 2009-03-04 | 2011-01-20 | Государственное образовательное учреждение высшего профессионального образования "Московская государственная академия тонкой химической технологии имени М.В. Ломоносова" | 1-гексадецил-5-(1-пиренбутил)-n-(l-орнитил)-l-глутамат бисхлорид |
RU2593367C2 (ru) | 2010-09-02 | 2016-08-10 | Дзе Скриппс Рисерч Инститьют | Основанная на наночастицах, нацеленная на опухоли доставка лекарственных средств |
US20120294924A1 (en) * | 2011-04-29 | 2012-11-22 | Thomas Tice | Peptide-Lipid Conjugates And Uses Thereof |
DK2825157T3 (da) * | 2012-03-16 | 2019-01-02 | Merck Patent Gmbh | Aminosyrelipider |
-
2013
- 2013-03-11 NO NO13710293A patent/NO2825156T3/no unknown
- 2013-03-11 KR KR1020147028906A patent/KR102208586B1/ko active IP Right Grant
- 2013-03-11 MX MX2014010808A patent/MX354811B/es active IP Right Grant
- 2013-03-11 US US14/384,702 patent/US9878044B2/en active Active
- 2013-03-11 JP JP2014561310A patent/JP6527331B2/ja active Active
- 2013-03-11 WO PCT/EP2013/000698 patent/WO2013135359A1/en active Application Filing
- 2013-03-11 CA CA2867169A patent/CA2867169C/en active Active
- 2013-03-11 CN CN201380013774.1A patent/CN104168888A/zh active Pending
- 2013-03-11 DK DK13710293.5T patent/DK2825156T3/en active
- 2013-03-11 KR KR1020207008113A patent/KR20200036033A/ko not_active Application Discontinuation
- 2013-03-11 NZ NZ631034A patent/NZ631034A/en unknown
- 2013-03-11 SG SG11201405552VA patent/SG11201405552VA/en unknown
- 2013-03-11 ES ES13710293.5T patent/ES2644778T3/es active Active
- 2013-03-11 AU AU2013231638A patent/AU2013231638B2/en active Active
- 2013-03-11 PT PT137102935T patent/PT2825156T/pt unknown
- 2013-03-11 EP EP13710293.5A patent/EP2825156B1/en active Active
- 2013-03-11 BR BR112014022451-0A patent/BR112014022451B1/pt active IP Right Grant
- 2013-03-11 RU RU2014141545A patent/RU2654210C2/ru active
- 2013-03-11 SG SG10201610401XA patent/SG10201610401XA/en unknown
- 2013-03-15 TW TW102109381A patent/TWI586370B/zh active
-
2014
- 2014-09-09 IL IL234550A patent/IL234550A/en active IP Right Grant
- 2014-10-15 ZA ZA2014/07490A patent/ZA201407490B/en unknown
- 2014-12-11 HK HK14112479.9A patent/HK1198924A1/xx unknown
-
2018
- 2018-01-11 US US15/867,985 patent/US11510988B2/en active Active
- 2018-01-12 AU AU2018200293A patent/AU2018200293B2/en active Active
- 2018-05-29 JP JP2018102256A patent/JP2018141015A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1198924A1 (en) | Targeting aminoacid lipids | |
IL236563A0 (en) | Direct search-driven contact | |
EP2830699A4 (en) | ASEPTIC CONNECTOR | |
EP2902071A4 (en) | INTERCONNECTS | |
HK1199819A1 (en) | Aminoacid lipids | |
EP2902073A4 (en) | CONNECTOR | |
EP2810685A4 (en) | CONNECTOR | |
EP2903140A4 (en) | GENERATOR | |
EP2891661A4 (en) | MITOCHONDRIAL TARGETING PEPTIDE | |
EP2833521A4 (en) | STATOR | |
EP2902689A4 (en) | CONNECTION | |
EP2902072A4 (en) | CONNECTOR | |
EP2911251A4 (en) | CONNECTOR | |
TWM475731U (en) | Connector | |
EP2871398A4 (en) | INTERCONNECTS | |
GB201215525D0 (en) | Elelectrical generator | |
EP2839756A4 (en) | INTERCONNECTS | |
EP2805385A4 (en) | INTERCONNECTS | |
EP2824376A4 (en) | CONNECTOR | |
GB2504497B (en) | Armour | |
EP2814560A4 (en) | CONNECTION | |
EP2879246A4 (en) | INTERCONNECTS | |
SG2013014170A (en) | Targeted liposomes | |
EP2852007A4 (en) | CONNECTOR | |
PL2877809T3 (pl) | Opancerzenie |